ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx provided misleading information regarding the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta, claiming confidence in the drug's efficacy while concealing material adverse facts [5][6]. - It is claimed that the positive statements made by the defendants led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor damages when the true information was revealed [6].